SARC Meeting
Venice, Italy
November 2, 2006
8:00-12:00

Chawla/Rosenfeld Developmental Therapeutics Symposia
8:00-8:30 mTOR inhibition/IGFR
   Lee Helman
8:30-9:00 Operationalizing the Choi Criteria
   Haesun Choi
   Robert Benjamin
   Scott Schuetze

SARC/European Collaboration
9:00-9:45 “SMART” Trial SARC008
   Sarcoma Maintenance Assessment Randomized Trial
   Larry Baker

9:45-10:00 BREAK

Ongoing Trials
10:00-10:10 SARC003
   Combination gemcitabine/docetaxel in Ewing’s Sarcoma, Osteosarcoma
   and Chondrosarcoma
   Shreyas Patel
10:10-10:15 SARC004
   Preoperative imatinib in DFSP
   Scott Schuetze
10:15-10:25 SARC005
   Adjuvant treatment of high risk uterine leiomyosarcoma
   Robert Maki
10:25-10:35 SARC006
   Treatment of malignant peripheral nerve sheath tumor in sporadic vs nf1
   associated
   Lee Helman
10:35-10:45 SARC007
   Perifosine in chemoresistant sarcoma
   Dejka Steinart
10:45-10:55 SARC009
   Dasatinib in selected sarcoma subtypes
   Scott Schuetze
10:55-11:05 SARC011
   Dasatinib in GIST
   Robert Benjamin
Concepts
11:05-11:15  Lilly Sponsored Study (SARC 010)
   Larry Baker

SARC Organization
11:15-11:25  New Concept: Submission Procedure and Review
   Robert Maki
11:25-11:35  Participation in SARC trials
   Robert Maki

11:35-12:00  Business Meeting